Physician profile
Eric Spann
NPI 1528145695
$705.29
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.31 · 2020: $52.08 · 2021: $69.47 · 2022: $139 · 2023: $136 · 2024: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $358.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $235.88 | 2022-2024 | Puraply |
| Amgen INC. | $165.97 | 2019-2023 | Repatha, Otezla |
| Xeris Pharmaceuticals, INC. | $80.90 | 2022-2023 | Gvoke Hypopen |
| Lilly USA, LLC | $42.55 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $31.01 | 2023-2024 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $29.17 | 2024 | Voquezna |
| Allergan, INC. | $22.39 | 2019 | |
| Merck Sharp & Dohme LLC | $17.00 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.10 | 2019 | |
| Glaxosmithkline, LLC. | $13.62 | 2024 | Trelegy Ellipta |
| Abbott Laboratories | $12.90 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.80 | 2022 | |
| Abbvie INC. | $12.67 | 2022 | |
| Pfizer INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Spann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.